Angel Azpeitia

Physician interested in #medicalmarketing, #innovation and #research in #pharma and #healthcare

[Derya Unutmaz, MD @DeryaTR_]

Excited to be part of this paper on immune system changes across the lifespan, from babies to old age, led by my friend & colleague Duygu Uçar at the Jackson Laboratory. I've attached an infographic explaining the key points relevant to immune aging. https://t.co/zndBCw4ME7

[Nieves Martinez Lago MD PhD @DraMartinezLago]

🧪 [68Ga]Ga-DOTATATE PET in metastatic epNEC (prospective study)

📈 High, uniform SSTR expression on DOTATATE PET: only 13%

⚠️ Most patients showed absent or heterogeneous uptake

🛑 Routine SSTR PET may have limited value in unselected epNECs

🔗 https://t.co/tY8wdImp9J
@OncoAlert

[Grupo GETNE @GrupoGetne]

🫁 Actualización clasificación de TNE pulmonares (IASLC)

🔹 Incorpora Ki-67 como criterio diagnóstico
🔹 Reconoce NET G3 pulmonar
🔹 Transición de “carcinoide” hacia “NET”
🔹 Integra de nuevos conocimientos moleculares

🎯 Más precisión diagnóstica y mejor estratificación

🔗 https://t.co/2iXcDEBW93

[Marta Araujo-Castro, MD, PhD @Marta_Araujo_C]

💢💢Ya queda menos para nuestro gran curso anual en tumores hipofisarios

#cushing #hipófisis #acromegalia

‼️Te esperamos‼️
@NeuroendocrinoS @sociedadSEEN

[Grupo GETNE @GrupoGetne]

🧬 GEP-NENs in Ontario (2000–2023)

✔️ 12,877 patients

📈 Incidence: 1.83 → 7.46/100,000
📈 10-y OS: 63.3%
📈 10-y CSS: 76.4%

🎯 >90% 10-y CSS without metastases
⚠️ 51.3% with metastatic disease

💡 Rising incidence appears driven by earlier detection of nonmetastatic disease

🔗 https://t.co/mTRDZAfZfI

[Grupo GETNE @GrupoGetne]

🧬 REGETNE-tiroides: RWE en CAT (n=214)

📈 mOS: 4.5 meses

🧪 Perfil molecular: mejor SG
🧪 BRAF V600E: mejor pronóstico
🧪 TERTp: peor pronóstico

🎯 IO, TKI, IO+TKI y terapias dirigidas: mayor supervivencia.

⚠️ Tratamiento local: impacto pronóstico, incluso en enfermedad M1

🔗 https://t.co/t6uBdurrvK

[Angela Lamarca @DrAngelaLamarca]

ZG006- Phase II trial with trispecific T Cell Engager DLL3/DLL3/CD3 in NEC at @ASCO #ASCO26

ORR if DLL3 high at 30 mg 56%, DOR 11.7 months

🙌🏻Consistent - DLL3 works in NEC

[NET- ESPAÑA @Netespana]

Muchas graciasss
Ahora urge pasar a la acción (pero de verdad), escuchar a los pacientes y ofrecer soporte nutricional y de ejercicio físico
🍽 🏃‍♀️
Nuestros datos hablan ... 🙏

[Maribel del Olmo @drdelolmo_mbel]

🔥 A new prediction tool for malnutrition and sarcopenia in patients with neuroendocrine neoplasms, highlighting the critical role of nutrition and the power of multidisciplinary teamwork across Spain. @GrupoGetne 🤝🥗📊

[Grupo GETNE @GrupoGetne]

🧠🍽️ #NUTRIGETNE (GETNE-S2109)

📌 Malnutrition in 62% of patients with GEP-NENs
📌 Sarcopenia in 15%
📌 New predictive score developed by @GrupoGetne to facilitate early nutritional screening in routine practice
💡 Simple, rapid and NET-specific tool.

🔗 https://t.co/NQtzIvWouH

[Marta Araujo-Castro, MD, PhD @Marta_Araujo_C]

📌Join us on 26 May for an insightful webinar on cortisol-producing #ACC

👉We’ll discuss diagnosis, molecular insights, and emerging therapeutic strategies with leading experts in the field
✍️Speaker: Dr. Terzolo

📅 26 May
🔗 Register here: https://t.co/5UcrKBPAq9
#ACC

[María Jesús Baena Moreno @maria_baenam]

Hoy ha arrancado el Preceptorship en Neoplasias Neuroendocrinas organizado por la Dra. Rocío García Carbonero @GCarboneroLab en el Hospital Universitario 12 de Octubre.
Dos días para profundizar en cómo abordar esta patología desde una perspectiva multidisciplinar. Enhorabuena👏🏼

[Grupo GETNE @GrupoGetne]

💊📊 Lower-dose everolimus in NETs

✔️ ≤6 mg/day reduced costs by ~42%
→ savings of ~$1137/patient/month

🔹 Drug acquisition = 91% of total expenditure

⚠️ Prior RWE suggests efficacy may be preserved

💡 Dose optimization may improve sustainability of NET care

🔗 https://t.co/wzEVVyRZ6M

[Grupo GETNE @GrupoGetne]

🧠📊 Cabo+nivo+ipi in PD NECs

✔️ Durable responses possible:
2 PRs lasting 27 & 17 months

⚠️ Overall activity limited:
ORR 12.5%
mPFS 2.7 months

🔹 Grade 3-4 TRAEs: 56%

💡 Study stopped early → regimen not supported for further development

🔗 https://t.co/72Yuf0Z4tM
@myESMO @GrupoGetne

[Marta Araujo-Castro, MD, PhD @Marta_Araujo_C]

It will be a pleasure to participate in this meeting on #acc #cushing
@ESEndocrinology @sociedadSEEN @ENSAT_news

[J Hernando @JHernando3]

Interested in thyroid / endocrine / neuroendocrine neoplasms❓️

Here a practical mini-guide to help navigate #ASCO26 and avoid missing relevant abstracts.

[NET- ESPAÑA @Netespana]

#10añosNET
Si eres paciente o familiar y todavía no te has inscrito en el próximo encuentro presencial en #Burgos todavía estás a tiempo
Juntos avanzamos para mejorar la VIDA de los pacientes 🦓🦓
@netcancerday
@GEPAC_
@ContraCancerBU
@GrupoGetne

🗓️ 15 de mayo
👇👇👇👇

[Grupo GETNE @GrupoGetne]

🧠✨ Ya está aquí la Preceptorship en Neoplasias Neuroendocrinas 2026

📍Madrid | 21-22 mayo
🔹 Diagnóstico multidisciplinar
🔹 PRRT y teragnosis
🔹 Casos clínicos y nuevas estrategias terapéuticas
🔹 Expertos nacionales en NEN

[Nieves Martinez Lago MD PhD @DraMartinezLago]

🧬💥 Daraxonrasib (RMC-6236) in RASmt PDAC

🔹 Pan-RAS(ON) inhibitor
🔹 ORR: 35% in 2L RAS G12-mutant PDAC
🔹 mPFS: 8.5 mo
🔹 mOS: 13.1 mo
🔹 Responses durable (~8 mo)

🚀 One of the most promising signals yet for targeting RAS-driven PDAC

🔗 https://t.co/pp8ZIa9Wqo
@OncoAlert

[Nieves Martinez Lago MD PhD @DraMartinezLago]

🧠 Lifestyle in cancer survivors

⚠️ Advice ≠ action
🔹 Many pts don’t receive counseling
🔹 Even fewer sustain healthy habits

💡 Counseling improves adherence → still underused

🎯 Big opportunity in routine oncology care

🔗 https://t.co/WG7kr5znRi
@OncoAlert @JAMAOnc @myESMO @_SEOM